search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Publications
  • Research
  • Publications
  • Article

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.

Thijn R Brummelkamp ,
Armida W M Fabius ,
Jasper Mullenders ,
Mandy Madiredjo ,
Arno Velds ,
Ron M Kerkhoven ,
René Bernards ,
Roderick L Beijersbergen

Abstract

The identification of the cellular targets of small molecules with anticancer activity is crucial to their further development as drug candidates. Here, we present the application of a large-scale RNA interference-based short hairpin RNA (shRNA) barcode screen to gain insight in the mechanism of action of nutlin-3 (1). Nutlin-3 is a small-molecule inhibitor of MDM2, which can activate the p53 pathway. Nutlin-3 shows strong antitumor effects in mice, with surprisingly few side effects on normal tissues. Aside from p53, we here identify 53BP1 as a critical mediator of nutlin-3-induced cytotoxicity. 53BP1 is part of a signaling network induced by DNA damage that is frequently activated in cancer but not in healthy tissues. Our results suggest that nutlin-3's tumor specificity may result from its ability to turn a cancer cell-specific property (activated DNA damage signaling) into a weakness that can be exploited therapeutically.

More about this publication

Nature chemical biology

Volume 2
Issue nr. 4
Pages 202-6
Publication date 01-04-2006

Full text links

Publisher website (DOI) 10.1038/nchembio774
Europe PubMed Central 16474381
Pubmed 16474381

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.